#None #schizophrenia #Spinogenix #Tazbentetol

Spinogenix's Innovative Clinical Trial for Schizophrenia

Overview of the Trial

On March 11, 2026, Spinogenix, Inc., a biopharmaceutical company that specializes in innovative treatments, announced the completion of patient enrollment for its Phase 2 clinical trial of Tazbentetol (previously known as SPG302), designed to address schizophrenia. This important milestone brings hope for those dealing with this debilitating psychiatric disorder. The trial focuses not only on managing symptoms but aims to improve overall quality of life for patients.

What is Tazbentetol?

Tazbentetol represents a new class of therapies known as synaptic regenerative treatment, targeting all three core symptom domains of schizophrenia: positive symptoms (like hallucinations and delusions), negative symptoms (including social withdrawal and lack of motivation), and cognitive symptoms (which may manifest as deficits in memory, attention, and language). Current antipsychotic medications primarily alleviate positive symptoms, leaving many patients struggling with cognitive and negative symptoms. Tazbentetol holds the potential to rectify this gap in treatment.

The Phase 2 trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, efficacy, tolerability, and pharmacodynamics of Tazbentetol. It has enrolled 32 patients diagnosed with schizophrenia, providing them with either a daily oral dose of the medication or a placebo for six weeks.

The Need for Effective Treatment

Schizophrenia is a complex disorder that affects around 1% of the global population. Currently available antipsychotic treatments are limited in scope, effectively managing only the positive symptoms. There is a critical need for advancements in treatment to address negative and cognitive symptoms which significantly diminish patients' quality of life. Dr. Stella Sarraf, the CEO of Spinogenix, highlighted that achieving full enrollment in this Phase 2 trial is a fundamental step toward delivering new treatment options for millions affected by schizophrenia. The company will present interim results at the upcoming Schizophrenia International Research Society Annual Congress in Florence, Italy, scheduled for March 26-29, 2026.

Expert Insights

Dr. David Walling, the Chief Clinical Officer at CenExel and the trial's Principal Investigator, noted the importance of exploring new treatment mechanisms like Tazbentetol. He stated that the drug could shift the treatment paradigm towards regenerative medicine, reclaiming structural elements, specifically synapses, that are compromised in schizophrenia. This could be revolutionary in developing more effective treatments.

In addition to standard assessments of symptom severity using scales like the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression of Improvement (CGI-I), the trial will also integrate EEG analysis. This neurophysiological biomarker has the potential to provide insightful data on treatment effects by measuring changes in synaptic density through EEG abnormalities.

About Spinogenix

Spinogenix is at the forefront of transforming the approach to treating neurodegenerative, neuropsychiatric, and neurodevelopmental disorders. Their pioneering research focuses on synaptic regeneration and correction, with Tazbentetol being one of their flagship therapies. The company is also working on SPG601, aimed at treating Fragile X Syndrome. Spinogenix has gained significant recognition in the field, securing FDA and EMA Orphan Drug designations for various conditions, affirming the urgent need for novel treatment solutions.

With Tazbentetol's Phase 2 trial enrollment complete, the biopharmaceutical community eagerly anticipates the preliminary findings that may pave the way for a new era of effective schizophrenia treatment. Spinogenix's commitment to innovation could lead to promising improvements in the lives of those affected by this challenging disorder.